Activin pathway inhibition and rapid progression of malignancy in pulmonary arterial hypertension: A case series and hypothesis.
Adriano R Tonelli, Kulwant S Aulak, Jana Berro et al.
✦ AI-curated · Sources linked
Case in brief
The report describes malignancies occurring in patients with pulmonary arterial hypertension (PAH) treated with sotatercept, an activin-pathway inhibitor. The abstract does not provide individual patient presentations, cancer types, diagnostic findings, or outcomes, so the clinical and diagnostic course cannot be summarized further. The authors note that these observations do not establish that sotatercept caused malignancy development or progression.
What made this case unusual
The report raises a potential association between sotatercept exposure and malignancy development or progression, including concern in patients with preexisting or latent malignancies; causality is not established.
Diagnostic / clinical pearl
In patients with PAH receiving sotatercept, remain vigilant for malignancy, while recognizing that this case series cannot establish a causal relationship.
Why it matters
The authors identify a need for further study of the long-term implications of activin-pathway inhibition in patients with existing or latent malignancy.